Compare DoorDash Inc (DASH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs TG Therapeutics Inc — how do they compare? DoorDash Inc trades at $213.75 (market cap $91.86B), while TG Therapeutics Inc trades at $49.64 (market cap $7.64B). The key difference: DoorDash Inc is far larger — about 12× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| DASH | TGTX | |
|---|---|---|
Market Cap | $91.86B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $59.06 |
52-Week Low | $146.60 | $26.94 |
Enterprise Value | $89.82B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $214.47, up 2.2% today, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $4.45 billion, up 36% year-over-year, though earnings per share of $0.46 missed estimates. Revenue growth remains robust, with 2025 revenue reaching $13.72 billion and net income turning positive at $935 million, marking sustained GAAP profitability.
The outlook is positive with 75.68% of analysts rating DASH a Buy and a consensus price target of $247.41, suggesting 15% upside. Key risks include elevated valuation multiples, rising R&D costs impacting margins, and competitive pressures in the delivery sector. Growth catalysts include international expansion and AI investments, but profitability sustainability remains a watch point.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
